Form 4: Contineum Therapeutics Chief Scientific Officer Sells Shares Under 10b5-1 Plan
SEC Form 4 Filing
Contineum Therapeutics' Chief Scientific Officer, Daniel S. Lorrain, sold 6,190 shares of Class A Common Stock under a pre-arranged 10b5-1 trading plan.
Summary
- Daniel S. Lorrain, Chief Scientific Officer of Contineum Therapeutics, sold 6,091 shares of Class A Common Stock at a weighted average price of $16.3738 per share.
- An additional 99 shares were sold at $17.05 per share.
- These transactions were executed on November 18, 2024, under a 10b5-1 trading plan adopted on August 19, 2024.
- Following these sales, Mr. Lorrain directly owns 169,572 shares of Class A Common Stock.
- Mr. Lorrain also indirectly owns 3,898 shares through his spouse, which includes 325 shares purchased through the company's Employee Stock Purchase Plan.
Sentiment
Score: 5
Explanation: The document is a routine SEC filing related to insider trading. It does not contain any information that would be considered positive or negative for the company's outlook.
Industry Context
This is a routine filing related to insider trading activity. It is common for executives to use 10b5-1 plans to sell shares to avoid accusations of trading on inside information.
Comparison to Industry Standards
- Form 4 filings are standard practice for publicly traded companies in the US, and this filing is consistent with those requirements.
- The use of a 10b5-1 trading plan is a common method for corporate insiders to sell shares while avoiding accusations of insider trading, and is a standard practice across the industry.
- The reported share sales are relatively small compared to the total outstanding shares of the company, and are not unusual for a company of this size.
Stakeholder Impact
- The share sales by the Chief Scientific Officer may have a minor impact on shareholder sentiment, but are unlikely to significantly affect the company's operations or financial position.
Key Dates
| Date | Description |
|---|---|
| 08/19/2024 | Date the 10b5-1 trading plan was adopted by the reporting person. |
| 11/18/2024 | Date of the stock sale transactions. |
| 11/20/2024 | Date the Form 4 was signed. |
Keywords
Contineum Therapeutics, insider trading, Form 4, 10b5-1 plan, stock sale, Daniel S. Lorrain, CTNM, Chief Scientific Officer
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.